The efficacy of recombinant interleukin 2 in local treatment of superficial bladder tumors

The present study was undertaken to assess the efficacy of recombinant Interleukin 2 (rIL-2: S-6820) in treatment of superficial bladder tumors. Three intratumor injections at a dose of 5 x 10(5) units/day via urethra, were performed every other day under endoscopic control in 12 patients with super...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 34(1988), 12 vom: 15. Dez., Seite 2115-9
1. Verfasser: Fujioka, T (VerfasserIn)
Weitere Verfasser: Shiraishi, M, Tanji, S, Sato, S, Koike, H, Aoki, H, Suzuki, K, Kumagai, K, Banya, Y, Kubo, T
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 1988
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:English Abstract Journal Article Interleukin-2 Receptors, Interleukin-2 Recombinant Proteins
LEADER 01000caa a22002652 4500
001 NLM032477430
003 DE-627
005 20250126153406.0
007 tu
008 231221s1988 xx ||||| 00| ||jpn c
028 5 2 |a pubmed25n0109.xml 
035 |a (DE-627)NLM032477430 
035 |a (NLM)3266444 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a jpn 
100 1 |a Fujioka, T  |e verfasserin  |4 aut 
245 1 4 |a The efficacy of recombinant interleukin 2 in local treatment of superficial bladder tumors 
264 1 |c 1988 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 28.04.1989 
500 |a Date Revised 15.11.2006 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a The present study was undertaken to assess the efficacy of recombinant Interleukin 2 (rIL-2: S-6820) in treatment of superficial bladder tumors. Three intratumor injections at a dose of 5 x 10(5) units/day via urethra, were performed every other day under endoscopic control in 12 patients with superficial bladder cancer. On the 15th day after completion of the series of injections, the tumor had disappeared in one patient and 50% regression over was observed in two other patients. Therefore, the response rate to the rIL-2 treatment in our study was 25.0%. Each tumor which responded to the therapy, was single, small and low grade. In the peripheral blood of the 12 patients, an increase in IL-2 receptor-positive lymphocytes and augmentation of natural killer activity were detected after the rIL-2 intratumor injection. There were no serious side effects except for moderate fever in our study 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Interleukin-2  |2 NLM 
650 7 |a Receptors, Interleukin-2  |2 NLM 
650 7 |a Recombinant Proteins  |2 NLM 
700 1 |a Shiraishi, M  |e verfasserin  |4 aut 
700 1 |a Tanji, S  |e verfasserin  |4 aut 
700 1 |a Sato, S  |e verfasserin  |4 aut 
700 1 |a Koike, H  |e verfasserin  |4 aut 
700 1 |a Aoki, H  |e verfasserin  |4 aut 
700 1 |a Suzuki, K  |e verfasserin  |4 aut 
700 1 |a Kumagai, K  |e verfasserin  |4 aut 
700 1 |a Banya, Y  |e verfasserin  |4 aut 
700 1 |a Kubo, T  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Hinyokika kiyo. Acta urologica Japonica  |d 1962  |g 34(1988), 12 vom: 15. Dez., Seite 2115-9  |w (DE-627)NLM012631779  |x 0018-1994  |7 nnns 
773 1 8 |g volume:34  |g year:1988  |g number:12  |g day:15  |g month:12  |g pages:2115-9 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_350 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2018 
951 |a AR 
952 |d 34  |j 1988  |e 12  |b 15  |c 12  |h 2115-9